Tomohiko Kimura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9089886/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice. Biochemical and Biophysical Research Communications, 2016, 470, 772-782.	1.0	56
2	Comparison of the effects of three kinds of glucoseâ€lowering drugs on nonâ€alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, openâ€label, threeâ€arm, active control study. Journal of Diabetes Investigation, 2020, 11, 1612-1622.	1.1	54
3	Beneficial effects of sodium–glucose cotransporter 2 inhibitors for preservation of pancreatic β â€cell function and reduction of insulin resistance. Journal of Diabetes, 2017, 9, 219-225.	0.8	51
4	Protective effects of pioglitazone and/or liraglutide on pancreatic β-cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes. Molecular and Cellular Endocrinology, 2015, 400, 78-89.	1.6	49
5	Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic β ells in <i>db/db</i> mice: The earlier and longer, the better. Diabetes, Obesity and Metabolism, 2018, 20, 2442-2457.	2.2	41
6	Multifaceted Mechanisms of Action of Metformin Which Have Been Unraveled One after Another in the Long History. International Journal of Molecular Sciences, 2021, 22, 2596.	1.8	36
7	Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus. Journal of Diabetes Research, 2018, 2018, 1-6.	1.0	28
8	Dietary restriction preserves the mass and function of pancreatic Î ² cells via cell kinetic regulation and suppression of oxidative/ER stress in diabetic mice. Journal of Nutritional Biochemistry, 2015, 26, 219-226.	1.9	26
9	Association of GA/HbA1c ratio and cognitive impairment in subjects with type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 2016, 30, 1452-1455.	1.2	25
10	Appropriate therapy for type 2 diabetes mellitus in view of pancreatic βâ€cell glucose toxicity: "the earlier, the better― Journal of Diabetes, 2016, 8, 183-189.	0.8	25
11	Unexpected Pleiotropic Effects of SGLT2 Inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class. International Journal of Molecular Sciences, 2021, 22, 3062.	1.8	23
12	Combination of DPP-4 inhibitor and PPARÎ ³ agonist exerts protective effects on pancreatic Î ² -cells in diabetic db/db mice through the augmentation of IRS-2 expression. Molecular and Cellular Endocrinology, 2015, 413, 49-60.	1.6	20
13	Down-regulation of vascular GLP-1 receptor expression in human subjects with obesity. Scientific Reports, 2018, 8, 10644.	1.6	19
14	Pancreatic alpha cells in diabetic rats express active GLP-1 receptor: Endosomal co-localization of GLP-1/GLP-1R complex functioning through intra-islet paracrine mechanism. Scientific Reports, 2018, 8, 3725.	1.6	15
15	Switching from lowâ€dose thiazide diuretics to sodium–glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension. Journal of Diabetes Investigation, 2018, 9, 875-881.	1.1	15
16	Favorable Effects of GLP-1 Receptor Agonist against Pancreatic β-Cell Glucose Toxicity and the Development of Arteriosclerosis: "The Earlier, the Better―in Therapy with Incretin-Based Medicine. International Journal of Molecular Sciences, 2021, 22, 7917.	1.8	15
17	Decreased glucagon-like peptide 1 receptor expression in endothelial and smooth muscle cells in diabetic <i>db/db</i> mice: TCF7L2 is a possible regulator of the vascular glucagon-like peptide 1 receptor. Diabetes and Vascular Disease Research, 2017, 14, 540-548.	0.9	14
18	Vascular endothelial PDPK1 plays a pivotal role in the maintenance of pancreatic beta cell mass and function in adult male mice. Diabetologia, 2019, 62, 1225-1236.	2.9	14

Τομομικό Kimura

#	Article	IF	CITATIONS
19	Molecular Mechanism of Pancreatic β-Cell Failure in Type 2 Diabetes Mellitus. Biomedicines, 2022, 10, 818.	1.4	10
20	Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2013, 101, 35-44.	1.1	9
21	Seven-year Observational Study on the Association between Glycemic Control and the New Onset of Macroangiopathy in Japanese Subjects with Type 2 Diabetes. Internal Medicine, 2016, 55, 1419-1424.	0.3	9
22	Advanced breast cancer in a relatively young man with severe obesity and type 2 diabetes mellitus. Journal of Diabetes Investigation, 2017, 8, 395-396.	1.1	9
23	There is a Close Association Between the Recovery of Liver Injury and Glycemic Control after SGLT2 Inhibitor Treatment in Japanese Subjects with Type 2 Diabetes: A Retrospective Clinical Study. Diabetes Therapy, 2018, 9, 1569-1580.	1.2	8
24	New prospects for incretinâ€related drugs in the treatment of type 2 diabetes. Journal of Diabetes Investigation, 2021, 12, 1141-1143.	1.1	8
25	Verification of Kumamoto Declaration 2013 and Glycemic Targets for Elderly Patients with Diabetes in Japan for prevention of diabetic complications: A retrospective longitudinal study using outpatient clinical data. Journal of Diabetes Investigation, 2019, 10, 290-301.	1.1	7
26	Association of the Glycemic Fluctuation as well as Glycemic Control with the Pancreatic β-cell Function in Japanese Subjects with Type 2 Diabetes Mellitus. Internal Medicine, 2019, 58, 167-173.	0.3	6
27	Case Report: Malignant Pheochromocytoma Without Hypertension Accompanied by Increment of Serum VEGF Level and Catecholamine Cardiomyopathy. Frontiers in Endocrinology, 2021, 12, 688536.	1.5	6
28	Clinical effects of liraglutide are possibly influenced by hypertriglyceridemia and remaining pancreatic β-cell function in subjects with type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 2016, 30, 1201-1203.	1.2	5
29	A case of tamoxifen-induced hypertriglyceridemia monitoring the changes in lipoprotein fractions over time. BMC Endocrine Disorders, 2021, 21, 115.	0.9	5
30	Human serum albumin: Possible cause of insulin autoimmune syndrome. Journal of Diabetes Investigation, 2016, 7, 919-920.	1.1	4
31	Werner Syndrome and Diabetes Mellitus Accompanied by Adrenal Cortex Cancer. Internal Medicine, 2017, 56, 1987-1992.	0.3	4
32	Suppression of free fatty acid receptor 1 expression in pancreatic β-cells in obese type 2 diabetic <i>db/db</i> mice: a potential role of pancreatic and duodenal homeobox factor 1. Endocrine Journal, 2019, 66, 43-50.	0.7	4
33	Efficacy and safety of adding ipragliflozin to insulin in Japanese patients with type 1 diabetes mellitus: a retrospective study. Endocrine Journal, 2021, 68, 1455-1461.	0.7	4
34	Case Report: A Variety of Immune-Related Adverse Events Triggered by Immune Checkpoint Inhibitors in a Subject With Malignant Melanoma: Destructive Thyroiditis, Aseptic Meningitis and Isolated ACTH Deficiency. Frontiers in Endocrinology, 2021, 12, 722586.	1.5	4
35	Efficacy and Safety of Switching from Insulin Glargine 100 U/mL to the Same Dose of Glargine 300 U/mL in Japanese Type 1 and 2 Diabetes Patients: A Retrospective Analysis. Internal Medicine, 2018, 57, 1381-1389.	0.3	3
36	Notable Underlying Mechanism for Pancreatic β-Cell Dysfunction and Atherosclerosis: Pleiotropic Roles of Incretin and Insulin Signaling. International Journal of Molecular Sciences, 2020, 21, 9444.	1.8	3

Τομομικό Κιμυγά

#	Article	IF	CITATIONS
37	Insulin allergy brought out 8Âyears after starting insulin therapy in a subject with type 1 diabetes mellitus. Acta Diabetologica, 2020, 57, 1025-1026.	1.2	3
38	Strawberry milk-like blood in a subject with diabetic lipemia: dramatic change to transparent color after insulin therapy. SpringerPlus, 2016, 5, 1499.	1.2	2
39	Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus. Journal of Diabetes Research, 2017, 2017, 1-8.	1.0	2
40	Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study. Frontiers in Endocrinology, 2021, 12, 714447.	1.5	2
41	Multiple endocrine neoplasia type 1 with a frameshift mutation in its gene accompanied by a giant cervical lipoma and multiple fatty deposits in the pancreas:Âcase report. BMC Endocrine Disorders, 2021, 21, 164.	0.9	2
42	Idiopathic Bilateral Extraocular Myositis in a Subject With Poorly Controlled Type 2 Diabetes Mellitus: Case Report. Frontiers in Medicine, 2021, 8, 700307.	1.2	2
43	Central Diabetes Insipidus Due to IgG4-related Hypophysitis That Required over One Year to Reach the Final Diagnosis Due to Symptoms Being Masked by Sialadenitis. Internal Medicine, 2022, 61, 3541-3545.	0.3	2
44	Influence of thyroid volume on the effect of methimazole in Japanese subjects with mild Graves' disease. European Journal of Internal Medicine, 2016, 36, e31-e32.	1.0	1
45	Temporal lobe epilepsy associated with GAD autoimmunity. Acta Diabetologica, 2017, 54, 321-323.	1.2	1
46	Administration of RAS Inhibitor before the Onset of Diabetic Nephropathy Counteracts the Adverse Effect of Chronic Hyperglycemia and Reduces the Augmentation of Urinary Albumin Excretion: A Retrospective Clinical Study. Journal of Diabetes Research, 2018, 2018, 1-5.	1.0	1
47	Onset of type 1 diabetes mellitus and heparinâ€induced thrombocytopenia in a patient with Basedow's disease and idiopathic thrombocytopenic purpura: Novel combination as autoimmune polyglandular syndrome. Journal of Diabetes Investigation, 2018, 9, 1381-1382.	1.1	1
48	Persistent Hypoglycemia Induced by Long-acting Insulin Degludec. Internal Medicine, 2021, , .	0.3	1
49	Metformin induces insulin secretion by preserving pancreatic aquaporin 7 expression in type 2 diabetes mellitus. Journal of Diabetes Investigation, 2022, 13, 227-229.	1.1	1
50	Glucagon Test Is a Useful Predictor of Withdrawal From Insulin Therapy in Subjects With Type 2 Diabetes Mellitus. Frontiers in Endocrinology, 2022, 13, 871660.	1.5	1
51	Clinical relevance of dual agonist of glucagon and glucagonâ€like peptideâ€1 receptors to achieve functional restoration of first†and secondâ€phase insulin secretion. Journal of Diabetes Investigation, 2022, 13, 1300-1302.	1.1	1
52	Vitamin D deficiency osteomalacia triggered by long-term social withdrawal and unbalanced diet in a Japanese middle-aged subject. Medicine (United States), 2022, 101, e28589.	0.4	0
53	Syndrome of inappropriate secretion of thyroid-stimulating hormone in a subject with galactorrhea and menstrual disorder and undergoing infertility treatment. Medicine (United States), 2021, 100, e28414.	0.4	0